Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R)

Inna Markovna Chen,Marco Donia,Christopher Aled Chamberlain,Agnete Witness Præst Jensen,Arianna Draghi,Susann Theile,Kasper Madsen,Jane Preuss Hasselby,Anders Toxværd,Estrid Høgdall,Torben Lorentzen,Eva Wilken,Poul Geertsen,Inge Marie Marie Svane,Julia Sidenius Sidenius Johansen,Dorte Nielsen

Social Science Research Network（2022）

引用 1|浏览13

暂无评分

摘要

•Ipilimumab/nivolumab/tocilizumab/radiation was evaluated in pancreatic cancer.•No clinically meaningful efficacy was observed.•No unanticipated safety signals were registered.•No changes in the tumour-infiltrating lymphocytes were induced.•The serum IL-6 level prior to treatment was associated with survival.

查看译文

关键词

Pancreatic cancer,Ipilimumab,Nivolumab,Tocilizumab,Stereotactic body radiotherapy,TRIPLE-R

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要